Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of two tapentadol PR 25 mg tablets versus one tapentadol PR 50 mg tablet under fed conditions
NL-OMON46632Phase 1Active, not recruiting
- Sponsor
- Grünenthal GmbH
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tapentadol in chronic pain (2 arms), sponsored by Grünenthal GmbH. Primary endpoints: AUC0-inf, AUC0-t and 1 more. Started May 2018; status: active, not recruiting.
02
Drugs
tapentadol
03
Conditions
chronic pain
Beyond the preview
Go deeper on NL-OMON46632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46632.